AZD8701 + Durvalumab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Cancer
Conditions
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Trial Timeline
Aug 18, 2020 → Oct 7, 2024
NCT ID
NCT04504669About AZD8701 + Durvalumab
AZD8701 + Durvalumab is a phase 1 stage product being developed by AstraZeneca for Clear Cell Renal Cell Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04504669. Target conditions include Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04504669 | Phase 1 | Completed |
Competing Products
20 competing products in Clear Cell Renal Cell Cancer